Analysts Raise Price Targets for Hims & Hers Health Amid Mixed Ratings

NEW YORK, NY — Analysts have evaluated Hims & Hers Health Inc. (HIMS) over the past three months, resulting in a range of opinions from bullish to bearish. A total of 13 analysts provided insights, which show an evolving sentiment regarding the company’s performance.

In recent ratings, the analysts offered two bullish, five indifferent, and three bearish views. The overall trend indicates a growing caution, with one bearish rating noted in the last 30 days compared to none in previous months.

The average price target for Hims & Hers Health stands at $36.85, significantly higher than last month’s average of $27.77, reflecting a 32.7% increase. The highest target is set at $68.00, while the lowest is $21.00, illustrating varying opinions on the company’s potential.

Key analyst changes include Daniel Grosslight from Citigroup, who lowered his rating from Sell to $25.00 from a previous target of $27.00. Jailendra Singh from Truist Securities also adjusted his rating to Hold, with a price target decreased to $33.00, down from $39.00.

Meanwhile, other analysts, like Maria Ripps of Canaccord Genuity, raised their ratings to Buy with a target of $68.00, a positive shift reflecting recent confidence in the company’s prospects.

As a telehealth platform, Hims & Hers Health connects consumers with licensed healthcare professionals, serving various health needs. The company has demonstrated impressive revenue growth, achieving a rate of 95.09% over three months, surpassing industry averages.

Their financial metrics indicate strength, with a net margin of 5.41% and a return on equity (ROE) of 5.68%, well above the industry standard. Additionally, the company’s conservative debt-to-equity ratio of 0.02 suggests a solid financial position.

Market analysts highlight the importance of their evaluations, noting that while they provide valuable insights, the unpredictability of market movements requires careful consideration by investors. As Hims & Hers Health continues to evolve, staying informed through analyst ratings could prove beneficial.